Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Matti Aapro, ESMO 2018 – Immunotherapy in Elderly Patients

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 6th 2018

Elderly patients are often under-represented in clinical trials and therefore may not receive the necessary treatment. Dr Matti Aapro explains that elderly patients should receive immunotherapy under the same circumstances as younger patients. While they may experience more treatment-related toxicity, the benefits can outweigh this, and therefore the side effects just require close management. Dr Aapro explains that the reason for under-representation of elderly patients in clinical trials is often do to strict inclusion criteria, which does not reflect the real-world population of these patients. They may also be more susceptible to adverse events, which could confound the results. There is also the misconception that elderly patients may harbour less immune responsiveness; this is not always true, as elderly patients can sometimes be fitter than their younger counterparts. Ultimately, inclusion should be based on the individual patient, rather than their age.

Questions:
1. To what extent is immunotherapy currently used in elderly patients? (0:11)
2. Why are elderly patients under-represented in clinical trials? (0:49)
3. What are the other major challenges in identifying elderly patients who may respond to immunotherapy? (2:30)
4. How are age-related changes in the immune system likely to affect the response of elderly patients to immunotherapy? (4:00)
5. What initiatives are ongoing to improve our understanding of the response of elderly people to immunotherapy? (5:36)

Speaker disclosures: Matti Aapro has nothing to disclose in relation to this interview.

Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup